Dachepalli Publishers to convene board meeting

Mumbai, May 4 -- Dachepalli Publishers will hold a meeting of the Board of Directors of the Company on 7 May 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Gujarat Ambuja Exports to table results

Mumbai, May 4 -- Gujarat Ambuja Exports will hold a meeting of the Board of Directors of the Company on 9 May 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Crestchem announces board meeting date

Mumbai, May 4 -- Crestchem will hold a meeting of the Board of Directors of the Company on 7 May 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Bank of India to discuss results

Mumbai, May 4 -- Bank of India will hold a meeting of the Board of Directors of the Company on 8 May 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Events TOMORROW - MAY 5: Sri Annapoorneshwari and Balamuri Ganapati Temple, 2nd Main, Lakshmipuram

India, May 4 -- 21st Anniversary Celebrations coinciding with Sankashtahara Chaturti, Panchamruta Abhisheka, 5 pm; Maha Ganapati and Annapoorneshwari Homa, 6.30 pm; Purnahuti, 8 pm; Mahamangalarati an... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and E... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and T... Read More

Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More

Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post... Read More

Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) ... Read More

• ««
• «
• 18561
• 18562
• 18563
• 18564
• 18565
• 18566
• 18567
• 18568
• 18569
• 18570
• »
• »»